Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
220 hedge funds and large institutions have $3.99B invested in Avidity Biosciences in 2025 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 98 increasing their positions, 65 reducing their positions, and 44 closing their positions.
51% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 65
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
7% more capital invested
Capital invested by funds: $3.71B → $3.99B (+$274M)
4.7% more ownership
Funds ownership: 106.99% → 111.68% (+4.7%)
7% less funds holding
Funds holding: 236 → 220 (-16)
32% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 44
70% less call options, than puts
Call options by funds: $9.04M | Put options by funds: $30.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$136M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$49.2M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$43.5M |
| 4 |
RI
RTW Investments
New York
|
+$25.4M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.9M |
| 2 |
BCM
Boxer Capital Management
San Diego,
California
|
-$26.9M |
| 3 |
Morgan Stanley
New York
|
-$21.4M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$20.2M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.9M |
RNAM Hedge Fund Activity: Q1 2025 in Review
220 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q1 2025, worth a combined $3.99B — up 7.4% from $3.71B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of RNAM and 30 opened new positions — a net loss of 14 holders — while 65 trimmed existing stakes and 98 added.
The largest buyer was Janus Henderson Group, adding an estimated $136M. The largest seller was Fidelity Investments, cutting an estimated $27.9M.
- 220 institutional investors held Avidity Biosciences (RNAM) as of Q1 2025, down from 236 in Q4 2024.
- Funds reported $3.99B of Avidity Biosciences stock for Q1 2025, up 7.4% quarter-over-quarter.
- 30 funds opened new Avidity Biosciences positions in Q1 2025 and 44 closed out, a net change of -14 holders.
- The largest Avidity Biosciences buyer in Q1 2025 was Janus Henderson Group, an estimated $136M added.
- The largest Avidity Biosciences seller in Q1 2025 was Fidelity Investments, an estimated $27.9M sold.
Based on aggregated 13F filings for Q1 2025.